Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Veru ( (VERU) ) just unveiled an announcement.
Veru Inc. entered into a Settlement Agreement with Onconetix, Inc., formerly known as Blue Water Vaccines Inc., to resolve outstanding payment obligations under previously issued promissory notes. On September 22, 2025, Veru agreed to accept a combination of cash, preferred stock, and warrants in full satisfaction of the debt, leading to the termination of the promissory notes and related agreements upon payment on September 24, 2025.
The most recent analyst rating on (VERU) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Veru stock, see the VERU Stock Forecast page.
Spark’s Take on VERU Stock
According to Spark, TipRanks’ AI Analyst, VERU is a Neutral.
Veru’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While the earnings call provided some optimism with positive clinical results and regulatory progress, the company’s financial challenges and valuation concerns weigh heavily on the score.
To see Spark’s full report on VERU stock, click here.
More about Veru
Average Trading Volume: 193,055
Technical Sentiment Signal: Sell
Current Market Cap: $50.57M
See more insights into VERU stock on TipRanks’ Stock Analysis page.